Protein / target
DNA-directed RNA polymerase subunit beta'
Protein at a glance
Biological role
DNA-directed RNA polymerase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates
Domains and Gene Ontology detail (22)Hide
Gene Ontology
- Ccytoplasm
- Ccytosol
- CDNA-directed RNA polymerase complex
- Cmembrane
- FDNA binding
- FDNA-directed RNA polymerase activity
- Fmagnesium ion binding
- Fzinc ion binding
- Pbacterial-type flagellum assembly
- Pbacterial-type flagellum-dependent cell motility
- Pcell motility
- Pcellular response to cell envelope stress
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell migration
- ·cell motility
Transcriptional regulation
- ·DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using th…
- ·DNA-templated transcription
- ·DNA-templated transcription initiation
- ·regulation of DNA-templated transcription elongation
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Bacterial DNA-directed RNA polymerase inhibitor
Indicated for Tuberculosis, Tuberculosis, Pulmonary
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
- Trial results posted
A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
- Regulatory approval
Approval: RIFAMPIN (ANDA219918)
- New publicationEstimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.